HDAC inhibitors (HDACi) are part of the therapeutic armamentarium against MM, and clinical studies have shown promising therapeutic activity of pan- or selective-HDACi when used within combination regimens [13]. The gene discussed is HDAC9; the disease is Miyoshi myopathy.